ATE231000T1 - Verwendung von parathyroid-hormon bestehend aus der aminosäuresequenz von 1-34 von human parathyroid-hormone zur reduzierung von knochenbrüchen sowohl im bereich der wirbelsaüle als auch anderer knochen - Google Patents

Verwendung von parathyroid-hormon bestehend aus der aminosäuresequenz von 1-34 von human parathyroid-hormone zur reduzierung von knochenbrüchen sowohl im bereich der wirbelsaüle als auch anderer knochen

Info

Publication number
ATE231000T1
ATE231000T1 AT99942350T AT99942350T ATE231000T1 AT E231000 T1 ATE231000 T1 AT E231000T1 AT 99942350 T AT99942350 T AT 99942350T AT 99942350 T AT99942350 T AT 99942350T AT E231000 T1 ATE231000 T1 AT E231000T1
Authority
AT
Austria
Prior art keywords
parathyroid hormones
bones
amino acid
acid sequence
bone fractures
Prior art date
Application number
AT99942350T
Other languages
German (de)
English (en)
Inventor
Janet M Hock
Gregory A Gaich
Willard H Dere
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE231000(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE231000T1 publication Critical patent/ATE231000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
AT99942350T 1998-08-19 1999-08-19 Verwendung von parathyroid-hormon bestehend aus der aminosäuresequenz von 1-34 von human parathyroid-hormone zur reduzierung von knochenbrüchen sowohl im bereich der wirbelsaüle als auch anderer knochen ATE231000T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Publications (1)

Publication Number Publication Date
ATE231000T1 true ATE231000T1 (de) 2003-02-15

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942350T ATE231000T1 (de) 1998-08-19 1999-08-19 Verwendung von parathyroid-hormon bestehend aus der aminosäuresequenz von 1-34 von human parathyroid-hormone zur reduzierung von knochenbrüchen sowohl im bereich der wirbelsaüle als auch anderer knochen

Country Status (32)

Country Link
US (2) US6977077B1 (https=)
EP (3) EP2266598B1 (https=)
JP (5) JP2002523375A (https=)
KR (1) KR100454207B1 (https=)
CN (1) CN1205997C (https=)
AR (1) AR033639A1 (https=)
AT (1) ATE231000T1 (https=)
AU (1) AU746277B2 (https=)
BR (1) BR9909445A (https=)
CA (1) CA2325371C (https=)
CO (1) CO5130020A1 (https=)
CY (2) CY1113343T1 (https=)
CZ (1) CZ301017B6 (https=)
DE (2) DE15152726T1 (https=)
DK (4) DK2266598T3 (https=)
DZ (1) DZ2873A1 (https=)
EA (1) EA003362B1 (https=)
ES (4) ES2393200T3 (https=)
HR (1) HRP20000755A2 (https=)
HU (2) HU1200430D0 (https=)
ID (1) ID29039A (https=)
IL (2) IL138829A0 (https=)
MY (1) MY129227A (https=)
NO (2) NO323984B1 (https=)
NZ (1) NZ507056A (https=)
PE (1) PE20001089A1 (https=)
PL (1) PL201688B1 (https=)
PT (4) PT1769804E (https=)
TR (1) TR200003455T2 (https=)
TW (1) TW576747B (https=)
UA (1) UA72205C2 (https=)
WO (1) WO2000010596A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
CA2387693A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
AU2003207512B2 (en) 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
KR20060058133A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 ｄ 유도체 및 부갑상선호르몬의 조합을 포함하는 약학 조성물 및 방법
MXPA06012980A (es) * 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
JP2008540522A (ja) * 2005-05-11 2008-11-20 ユニジーン・ラボラトリーズ・インコーポレーテッド 骨の形成および保存を促進するための方法
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
PL2136850T3 (pl) 2007-04-13 2012-07-31 Kuros Biosurgery Ag Polimeryczny uszczelniacz tkankowy
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
CA2710798A1 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
ES2662018T3 (es) * 2009-09-09 2018-04-05 Asahi Kasei Pharma Corporation Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
WO2012169435A1 (ja) 2011-06-07 2012-12-13 旭化成ファーマ株式会社 高純度ｐｔｈ含有凍結乾燥製剤およびその製造方法
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA3013443C (en) 2016-02-01 2021-06-15 Eli Lilly And Company Parathyroid hormone - anti-rankl antibody fusion compounds
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP6618139B1 (ja) 2018-10-29 2019-12-11 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
WO1996019246A1 (en) * 1994-12-19 1996-06-27 Beth Israel Hospital Association Continuous low-dose administration of parathyroid hormone or its agonist
CA2206657C (en) * 1994-12-22 2009-05-19 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, pth
JPH08310965A (ja) 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
RS49707B (sr) * 1997-09-09 2007-12-31 F.Hoffmann-La Roche Ag., Primena polipeptidnog analoga peptida srodnog paratireoidnom hormonu i njegovih soli za proizvodnju medikamenata za lečenje preloma kostiju
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
JP2014139220A (ja) 2014-07-31
CZ20004134A3 (cs) 2001-08-15
HU230697B1 (hu) 2017-09-28
JP6177718B2 (ja) 2017-08-09
ID29039A (id) 2001-07-26
JP2017190332A (ja) 2017-10-19
EP1059933B1 (en) 2003-01-15
JP2015028065A (ja) 2015-02-12
DE69904918T2 (de) 2003-11-13
PT1059933E (pt) 2003-06-30
AU746277B2 (en) 2002-04-18
ES2549551T1 (es) 2015-10-29
ES2621653T3 (es) 2017-07-04
DZ2873A1 (fr) 2003-12-15
PE20001089A1 (es) 2000-11-04
US7163684B2 (en) 2007-01-16
KR20010072763A (ko) 2001-07-31
DK2907522T3 (en) 2017-10-23
CZ301017B6 (cs) 2009-10-14
AR033639A1 (es) 2004-01-07
TW576747B (en) 2004-02-21
ES2393200T3 (es) 2012-12-19
BR9909445A (pt) 2000-12-12
CA2325371A1 (en) 2000-03-02
NO20005947D0 (no) 2000-11-24
JP2011021035A (ja) 2011-02-03
HRP20000755A2 (en) 2001-02-28
WO2000010596A1 (en) 2000-03-02
ES2549551T3 (es) 2017-11-27
EP2266598B1 (en) 2017-02-22
HK1030545A1 (en) 2001-05-11
DK2907522T1 (da) 2015-10-19
DK2266598T3 (en) 2017-05-15
US20050197294A1 (en) 2005-09-08
TR200003455T2 (tr) 2001-06-21
CY1113343T1 (el) 2016-06-22
EP2266598A1 (en) 2010-12-29
NZ507056A (en) 2003-10-31
DE15152726T1 (de) 2015-12-10
PL343595A1 (en) 2001-08-27
DE69904918D1 (de) 2003-02-20
EP2907522A1 (en) 2015-08-19
CA2325371C (en) 2004-08-17
CO5130020A1 (es) 2002-02-27
EP1059933A1 (en) 2000-12-20
HUP0101594A3 (en) 2002-01-28
ES2190244T3 (es) 2003-07-16
NO323984B1 (no) 2007-07-30
HUP0101594A2 (hu) 2001-11-28
AU5575099A (en) 2000-03-14
EA003362B1 (ru) 2003-04-24
PT2907522T (pt) 2017-10-23
PL201688B1 (pl) 2009-04-30
HU1200430D0 (hu) 2001-11-28
NO20072983L (no) 2000-11-24
EP2907522B1 (en) 2017-08-02
HK1212602A1 (en) 2016-06-17
US6977077B1 (en) 2005-12-20
CN1308545A (zh) 2001-08-15
IL138829A0 (en) 2001-10-31
EA200001015A1 (ru) 2001-02-26
PT1769804E (pt) 2012-11-13
IL138829A (en) 2011-01-31
NO20005947L (no) 2000-11-24
JP2002523375A (ja) 2002-07-30
MY129227A (en) 2007-03-30
HK1102496A1 (en) 2007-11-23
CY1119552T1 (el) 2018-03-07
KR100454207B1 (ko) 2004-10-26
DK1769804T3 (da) 2012-10-15
DK1059933T3 (da) 2003-04-07
CN1205997C (zh) 2005-06-15
PT2266598T (pt) 2017-05-02
UA72205C2 (uk) 2005-02-15

Similar Documents

Publication Publication Date Title
ATE231000T1 (de) Verwendung von parathyroid-hormon bestehend aus der aminosäuresequenz von 1-34 von human parathyroid-hormone zur reduzierung von knochenbrüchen sowohl im bereich der wirbelsaüle als auch anderer knochen
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE60018247D1 (de) System und Methode zur Verwendung mit bildgebenden Verfahren zur Erleichterung der Planung von chirurgischen Eingriffen
DE50010833D1 (de) Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
DE69834560D1 (de) Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut
ATE447552T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE59810847D1 (de) Verfahren zur form- und volumengebung von humanhaaren
DE59809812D1 (de) Knochen- und knorpel-ersatzstrukturen
DE69423031D1 (de) Vorrichtung zur Zusammenfügung von Knochenbrüchen im oberen Femurende
ID23822A (id) Pengangkatan kartu dan pengeluarannya
DE69522188D1 (de) Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
ATA288986A (de) Vorrichtung zur osteosynthese von knochenfragmenten, insbesondere zur fixation von knochenfrakturen
ATE446077T1 (de) Vektoren mit beiden isoformen von beta- hexosaminidase
ATE224731T1 (de) Verwendung von melanomhemmendem faktor zur reparatur von knorpelgewebe und knochen
ATE323685T1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60026500D1 (de) Polypeptid aus stratum corneum und seine verwendung
ATE274493T1 (de) Diarylselenid-verbindungen und ihre verwendung in menschliche oder tierische medizin wie in kosmetologie
DK0753995T3 (da) Fremstilling og anvendelse af varmebehandlede mesomorfe faser i næringsmiddelprodukter
DE60313301D1 (de) Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
ATE362923T1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
DE59508965D1 (de) Verfahren zur Herstellung von 4,6-Dichlor- oder 2,4,6-Trichlorpyrimidin aus 4,6-Dihydroxypyrimidin oder Barbitursäure
FI960064L (fi) Uudet peruskudoksen solulinjat ihmisen luuytimestä ja niiden käyttö
DE69419308D1 (de) Vorrichtung zur bestimmung von physiologischen daten sowie verwendung der vorrichtung
DE60238490D1 (de) Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1059933

Country of ref document: EP

RZN Patent revoked